CO-ORGANIZED BY

FONDAZIONE MENARINI

OTTO VON GUERICKE UNIVERSITÄT MAGDEBURG

LMU KLINIKUM DER UNIVERSITÄT MÜNCHEN

50 YEARS OF FONDAZIONE MENARINI



INTERNATIONAL CONGRESS ON:

Helicobacter Pylori: Global Consensus Conference

WWW.FONDAZIONE-MENARINI.COM

4th-7th November, 2026

Auditorium Fondazione Menarini Piazza Giuseppe Garibaldi, 30, 50014 Fiesole FI (Italy)

WHO WE ARE

50 YEARS OF FONDAZIONE MENARINI

The **"Fondazione Menarini"** was established in the spring of **1976** to promote research and knowledge in the fields of biology, pharmacology and medicine as well as economy and human sciences.
One of the main tools the Foundation uses to achieve its goals is the organization of **international congresses** with a specific focus on medical disciplines.



FONDAZIONE MENARINI

The logo the **Fondazione Menarini** adopted at the time of its establishment derives from a famous seventeenth-century treatise, the **Novissima Iconologia del Ripa** (Ripas' New Iconology), rich in symbolic meanings from Parmenides to Plato's Myth of the Soul.
The image, which depicts a man leading a horse while firmly gripping the bridle, was chosen as it effectively represents the Foundation's goals and topics based on its **balanced interests in humanistic and biological sciences.**



FONDAZIONE MENARINI

INTRO SPEECH

H.pylori infection is the most frequent chronic bacterial infection worldwide and localized within the stomach ,the specific target organ. The estimated prevalence of the H.pylori infection in the world population is 4.4 billion. All infected will develop chronic gastritis. Approximately 20 % of the infected individuals will develop symptoms and /or clinical complications during their lifetime. H.pylori induced dyspepsia and peptic ulcer disease are curable through eradication of the microorganism while the most severe complication ,gastric cancer requires complex oncological therapies. Gastric cancer is the fourth leading cause of mortality among all malignant diseases.90 % of the cases with gastric cancer are attributed to H.pylori infection and though no longer curable by H.pylori eradication it has become a preventable disease by H.pylori screen and treat strategies. Following the successful implementation of diverse strategies of screen and treat in high risk individuals and selected population groups have now based on results from the most recent clinical research, led to the ambition to increasingly raise this prevention concept to a global level. The ultimate mission and desire is to make a healthy stomach possible for the entire world population

However for the global implementation of such strategies we are facing crucial challenges such as the need to defeat the increasing H.pylori antibiotic resistance, reach out for solutions concerning the complex and jeopardizing interaction of antibiotics with gut microbiota, for issues related to logistics and costs-effectiveness in public health driven measures of general disease prevention. The conference „Maastricht VII/Florence towards a global consensus in H.pylori management“ will now be completed with the face to face meeting here in Fiesole/Florence following a long process of preparation .

The structure of the meeting has been composed of 3 working groups that elaborated specific statements in key areas guiding the management of H.pylori infection.

WG 1 Strategies for primary and secondary prevention of gastric cancer and other pathologies at the individual, selected cohort and population level, Public Health &-Economic related issues

WG 2 Diagnostic aspects, antibiotic resistance related issues

WG 3 Treatment adapted to global demands, Future directions originating from basic and translational clinical research , novel non-antibiotic principles for prevention and cure of H.pylori infection

President of the Meeting
Peter Malfertheiner

UNDER THE AUSPICES OF

European Helicobacter and Microbiota Study Group

PRESIDENT

Peter Malfertheiner (Munich, GE)

STEERING COMMITTEE OF THE MEETING:

Emad El Omar (Sydney, AU)
Jyh Ming Liou (Taipei, TW)
Steven Moss (Providence, US)
Massimo Rugge (Padua, IT)
Christian Schulz (Munich, GE)

CONSENSUS SCIENTIFIC SECRETARY:

Riccardo Vasapolli (Munich, GE)

CO-ORGANIZED BY

FONDAZIONE MENARINI

Fondazione Menarini
Centro Direzionale Milanofiori
20089 Rozzano (Milan, Italy)
Edificio N - Strada 8
Phone +39 02 55308110 - Fax +39 02 55305739
milan@fondazione-menarini.it
www.fondazione-menarini.com

ORGANIZING/ SCIENTIFIC SECRETARIAT

MARBEN S.R.L.
Via Melzi d'Eril, 20
20154 Milano
Tel. +39023491732
Fax +39023491629
www.marben.it

WEDNESDAY, 4TH NOVEMBER 2026 - AFTERNOON

04.30 p.m. - 06.30 p.m. Pre-meeting

THURSDAY, 5TH NOVEMBER 2026 - MORNING

08.30 a.m. - 08.40 a.m. Welcome addresses and Introduction of the Maastricht VII/Florence Consensus
P. Malfertheiner (Munich, GE)

08.40 a.m. - 08.50 a.m. Presentation of Fondazione Menarini
G. Caracciolo (Florence, IT)

SESSION I - CLINICAL MANAGEMENT - WG1

Chairpersons: **J. M. Liou** (Taipei, TW), **M. Rugge** (Padua, IT)

08.50 a.m. - 09.10 a.m. Lecture
Epidemiological Trends of H.pylori infection and Gastric cancer
J. Y. Park (Geneva, CH)

09.10 a.m. - 10.30 a.m. Panel of presenters
B.W. Kim (Seoul, KR), **M. Leja** (Riga, LV), **J.Y. Park** (Geneva, CH)**, K. Sugano** (Shimotsuke, JP), **B. Tepes** (Ljubljana, SI)

Questions and related statements

- What is the public health burden of H. pylori infection today?
- What reduction of disease burden -malignant and non-malignant diseases- can be achieved by screen and treat strategies?
- What is the relative impact of H.pylori on the development of distal and proximal cancer, and at the GE junction?
- Which diagnostic tests are preferred for population-based H. pylori screening?
- Can serology be used for H. pylori screening in low-prevalence populations, and how should positives be managed?
- Can H. pylori screening be integrated into existing preventive health platforms?
- Can serologic panels (Hp-Ab, PgI/PgII, gastrin) stratify individual GC risk? Are they an adequate tool eliminate for surveillance of post-eradication residual risk?
- Do host genetics, immune response, and environmental exposures modify gastric cancer risk in H. pylori–infected individuals?

10.30 a.m. - 10.45 a.m. Discussion and voting

10.45 a.m. - 11.10 a.m. *Coffee Break*

Chairpersons: **J. M. Liou** (Taipei, TW), **M. Rugge** (Padua, IT)

11.10 a.m. - 12.45 p.m. Panel of presenters
B.W. Kim (Seoul, KR), **M. Leja** (Riga, LV), **J.Y. Park** (Geneva, CH), **K. Sugano** (Shimotsuke, JP), **B. Tepes** (Ljubljana, SI)

Questions and related statements

- Which epidemiologic parameters most strongly determine gastric cancer risk at the population-level and its preventability?
- Up to which histological stage (OLGA/OLGIM) can H.pylori eradication reliably prevent gastric cancer?
- Up to what age are non-invasive tests for H. pylori infection appropriate for gastric cancer prevention in symptomatic and asymptomatic populations?
- Is general population-based H. pylori screening and eradication cost-effective for gastric cancer prevention?
- What population-level epidemiological, socioeconomic, and health-system factors should be incorporated when modelling gastric cancer prevention strategies across different populations?
- Does the prevalence of autoimmune gastritis vary with population-specific H. pylori epidemiology?
- Is there a causative mechanistic role of autoimmune gastritis in gastric carcinogenesis?
- Can we rely on the diagnostic accuracy of AI-assisted endoscopy for detecting atrophic gastritis and intestinal metaplasia? And can we omit histology?
- Are there new approaches to improve the identification of patients who carry increased risk for H. pylori related gastric cancer and warrant eradication?

12.45 p.m. - 01.00 p.m. Discussion and voting

01.00 p.m. - 02.00 p.m. *Lunch*

THURSDAY, 5TH NOVEMBER - AFTERNOON

SESSION II - DIAGNOSTICS AND RESISTANCE TO ANTIBIOTICS WG2

Chairpersons: **S. Moss** (Providence, US), **C. Schulz** (Munich, GE)

02.00 p.m. - 02.10 p.m. Lecture
Introduction to challenges of antibiotics resistance in H. pylori
TBD

02.10 p.m. - 04.00 p.m. Panel of presenters
V. Kayamba (Lusaka, ZM), **F. Megraud** (Bordeaux, FR), **A. Riquelme** (Santiago, CL), **S. Suerbaum** (Munich, GE)

Questions and generated statements

- What is the relevance of H. pylori and other microbial resistance in the context of H.pylori eradication therapy?
- Should antimicrobial susceptibility testing be performed routinely before first-line treatment initiation?
- What is known about H. pylori resistance rates from a global perspective?
- Should H. pylori antimicrobial susceptibility rates be routinely collected and monitored by health care systems, in order to develop stewardship programs and guide H. pylori treatment locally?
- Are molecular-based (genetic) antimicrobial susceptibility tests ready for clinical application?
- What are the relative advantages/disadvantages of molecular versus culture-based tests for antimicrobial susceptibility?
- Is antimicrobial susceptibility testing possible without performing endoscopy?

04.00 p.m. - 04.15 p.m. Discussion and voting

04.15 p.m. - 04.30 p.m. *Coffee Break*

Chairpersons: **S. Moss** (Providence, US),
C. Schulz (Munich, GE)

04.30 p.m. - 05.45 p.m. Panel of presenters
V. Kayamba (Lusaka, ZM), **A. Riquelme** (Santiago, CL),
S. Suerbaum (Munich, GE)

Questions and generated statements

- Should clarithromycin and levofloxacin -containing regimens only be used based on susceptibility testing?
- Is a positive serological test alone sufficient to start eradication treatment or is a confirmatory urea breath or stool antigen test always required?
- Can prolonging treatment duration or increasing antibiotic dosing help overcome resistance/improve treatment outcome?
- Can alternative Nitromidazole compounds as used in Asia or Chile, or rifasutenizol [combination of rifabutin and MNZ], or nitozanoxide be substitutued for metronidazole to overcome metronidazole resistance?
- For H. pylori infected subjects with the gastric preneoplastic changes of atrophy or IM, should the approach regarding AST be different to that for the general H. pylori infected population?
- How does H. pylori affect gut microbiota composition and what changes (short/long term) are expected following eradication therapy?
- How does H. pylori eradication therapy influence antibiotic resistance development (short/long term) of gut microbiota?

05.45 p.m. - 06.00 p.m. Discussion and voting

06.00 p.m. - 06.15 p.m. Survey event: Satisfaction survey with certificate

06.15 p.m. End of the day

FRIDAY, 6TH NOVEMBER 2026 -MORNING

SESSION III - TREATMENT – WG3

Chairpersons: **E. El Omar** (Sydney, AU),
P. Malfertheiner (Munich, GE)

09.00 a.m. - 09.20 a.m. Evolution and optimization of H. pylori eradication regimens
J. Gisbert (Madrid, SP), **C. O'Morain** (Dublin, IE)

09.20 a.m. - 10.30 a.m. Panel of presenters
J. Gisbert (Madrid, SP), **R. H. Hunt** (London, UK),
G. Ianiro (Rome, IT), **C. O' Morain** (Dublin, IE),
T. Rokkas (Athens, GR)

Questions and related statements

- What level of eradication efficacy is required for selection of the first line eradication regimen?
- Is regional eradication efficacy essential for the selection of the first line eradication regimen?
- What are the components required for Bismuth Quadruple therapy if intended for use as empiric first line?
- Which cut-off for H. pylori resistance to clarithromycin in the local/regional setting provides a valid measure for first line treatment selection?
- Which treatment strategy should be favoured if empiric therapy is proven equally effective compared to AST adapted therapy in a local setting? For what reasons?
- Does the selection of antibiotic influence the selection and dosage of acid suppressants?
- If available, are P-CABs preferred over PPI?
- In dual therapies with amoxicillin is tid administration always required?

10.30 a.m. - 10.45 a.m. Discussion and voting

Chairpersons: **E. El Omar** (Sydney, AU),
P. Malfertheiner (Munich, GE)

10.45 a.m. - 12.45 p.m. Panel of presenters
J. Gisbert (Madrid, SP), **R. H. Hunt** (London, UK),
G. Ianiro (Rome, IT), **C. O' Morain** (Dublin, IE),
T. Rokkas (Athens, GR)

Questions and related statements

- How should we proceed in the selection of therapy if first line failed?
- What therapy should be used in third line and what are the selection criteria?
- Are there novel options for H. pylori eradication without use of conventional antibiotic therapy?
- What is the evidence to pursue the development of a therapeutic vaccine?
- Are there targets specific to the pathobiology of H. pylori useful for novel drug development?
- Have probiotics the potential to substitute antibiotics for H.pylori eradication in future?
- Are Probiotics essential partners of antibiotic therapy in H. pylori eradication?
- When should a probiotic, which and for how long be combined with the antibiotic therapy?

12.45 p.m. - 01.00 p.m. Discussion and voting

01.00 p.m. - 02.00 p.m. *Lunch*

FRIDAY, 6TH NOVEMBER 2026 - AFTERNOON

SESSION IV - FINAL VOTING AND DISCUSSION OF ALL INDIVIDUAL STATEMENTS WITH ON LINE PARTICIPATION OF GLOBAL KOL

Chairpersons: **E. El Omar** (Sydney, AU), **J. M. Liou** (Taipei, TW), **P. Malfertheiner** (Munich, GE), **S. Moss** (Providence, US), **M. Rugge** (Padua, IT), **C. Schulz** (Munich, GE)

02.00 p.m. - 03.30 p.m.	Voting – part I
03.30 p.m. - 04.00 p.m.	*Coffee Break*
04.00 p.m. - 05.00 p.m.	Voting – part II
05.00 p.m. - 05.15 p.m.	Concluding remarks and adjourn
05.15 p.m. - 05.30 p.m.	Survey event: Satisfaction survey with certificate
05.30 p.m.	End of the day

SATURDAY, 7TH NOVEMBER 2026 - MORNING

09.00 a.m. - 11.00 a.m.	Post-meeting

FACULTY

Emad El Omar	University of New South Wales (UNSW), St George & Sutherland Clinical School / Microbiome Research Centre Sydney (AU)
Javier P. Gisbert	La Princesa University Hospital (IIS-Princesa), Autonomous University of Madrid (UAM), CIBEREHD, Madrid (SP)
Richard Hunt	McMaster University, Hamilton, Ontario CA London (UK)
Gianluca Ianiro	CEMAD, Agostino Gemelli University Hospital Foundation, IRCCS Rome (IT)
Violet Kayamba	University of Zambia Lusaka (ZM)
Byung-Wook Kim	Incheon St. Mary's Hospital, College of Medicine The Catholic University of Korea Seoul (KR)
Marcis Leja	University of Latvia Riga (LV)
Jyh-Ming Liou	National Taiwan University Hospital Taipei (TW)
Peter Malfertheiner	Otto von Guericke University Magdeburg & LMU University Hospital Munich (GE)
Steven Moss	Brown University Providence (US)
Colm O'Morain	Trinity College Dublin and Tallaght University Hospital Dublin (IE)
Jin Young Park	World Health Organization Geneva (CH)

FACULTY

Arnoldo Riquelme	Pontifical Catholic University of Chile UC Christus Health Network Center for Cancer Prevention and Control (CECAN) Santiago (CL)
Theodore Rokkas	Henry Dunant Hospital, Athens, Greece European University of Cyprus Athens (GR)
Massimo Rugge	University of Padua Padua (IT)
Christian Schulz	LMU University Hospital Munich (GE)
Sebastian Suerbaum	Max von Pettenkofer Institute LMU University Hospital Munich (GE)
Kentaro Sugano	Jichi Medical University Shimotsuke city, Tochigi prefecture Shimotsuke (JP)
Bojan Tepes	Medical Center Rogaska, Rogaska Slatina; National Institute of Public Health (NIPH), Ljubljana Faculty of Medicine, University of Ljubljana Ljubljana (SI)
Riccardo Vasapolli	Otto von Guericke University Magdeburg & LMU University Hospital Munich (GE)

REGISTRATION - HYBRID EVENT

VIA WEBSITE AND/OR APP - HYBRID EVENT

Subscription to the Reserved Area and to the Event of your interest is required.
REGISTRATION IS FREE.

RESIDENTIAL EVENT

Via website **www.fondazione-menarini.com**

IF YOU ARE ALREADY A SUBSCRIBER TO THE FONDAZIONE MENARINI RESERVED AREA

1) Please visit the page of the congress of your interest:
www.fondazione-menarini.com
2) Click on "SUBSCRIBE TO RESIDENTIAL EVENT" and LOG IN with your credentials.
3) Choose which days you wish to attend.

You will receive a confirmation email including your registration QR CODE for entering the event.

IF YOU ARE NOT YET A SUBSCRIBER, REGISTER FOR FREE IN THE FONDAZIONE MENARINI RESERVED AREA

1) Go to **www.fondazione-menarini.com** and click on "Reserved Area" (home page, on the right)
2) To register in the reserved area, just fill in the form, available here:
www.fondazione-menarini.com/en/reserved-area.html
3) Fill in all the mandatory fields and complete the registration, click on REGISTER (only once).
Wait for the confirmation page to appear, do not click on anything or leave the page.
Once you receive confirmation, return to the home page, you will already be logged-in to the reserved area.
4) Visit the page of the congress of your interest:
www.fondazione-menarini.com
5) Confirm your registration by clicking on "SUBSCRIBE TO RESIDENTIAL EVENT" and LOG IN with your credentials.
6) Choose which days you wish to attend.

You will receive a confirmation email including your registration QR CODE for entering the event.

REGISTRATION - LIVE STREAMING

LIVE STREAMING

Via website **www.fondazione-menarini.com**

IF YOU ARE ALREADY A SUBSCRIBER TO THE FONDAZIONE MENARINI RESERVED AREA

1) Please visit the page of the congress of your interest:
www.fondazione-menarini.com
2) Click on "SUBSCRIBE TO LIVE STREAMING" and LOG IN with your credentials, check the Privacy Notice and click on "ATTEND".

You can enjoy the LIVE STREAMING for free on 5th and 6th November 2026.

IF YOU ARE NOT YET A SUBSCRIBER, REGISTER FOR FREE IN THE FONDAZIONE MENARINI RESERVED AREA

1) Go to **www.fondazione-menarini.com** and click on "Reserved Area" (home page, on the right).
2) To register in the reserved area, just fill in the form, available here:
www.fondazione-menarini.com
3) Fill in all the mandatory fields and complete the registration, click on REGISTER (only once).
Wait for the confirmation page to appear, do not click on anything or leave the page.
Once you receive confirmation, return to the home page, you will already be logged-in to the reserved area.
4) Visit the page of the congress of your interest:
www.fondazione-menarini.com
5) Confirm your registration by clicking on "SUBSCRIBE TO LIVE STREAMING", check the Privacy Notice and click on "ATTEND".

You can enjoy the LIVE STREAMING for free on 5th and 6th November2026.

REGISTRATION - FONDAZIONE APP



VIA FONDAZIONE MENARINI APP

Download the APP of Fondazione Menarini,
click here or scan the QR CODE:

www.fondazione-menarini.com/en/app-fondazione-menarini.html

LIVE STREAMING

IF YOU ARE ALREADY A SUBSCRIBER TO THE FONDAZIONE MENARINI RESERVED AREA
You can access the APP with the same username and password that you use in the website. Visit the page of the event and confirm your participation, click on "SUBSCRIBE TO LIVE STREAMING".
You can enjoy the LIVE STREAMING for free on 16th and 18th September 2026.

IF YOU ARE NOT YET A SUBSCRIBER, REGISTER FOR FREE IN THE FONDAZIONE MENARINI RESERVED AREA
Click on the profile icon in the top right-hand corner, or in the details of an event. Click on LOGIN:
Click on the red button REGISTER; to register in the reserved area, just fill in all the mandatory fields of the form.
Now it is necessary to log in with your username (email) and password! Then click on LOGIN.
Now you are logged-in to the APP (you will see your name near the user icon).
You can visit the schedule of the event, and click on the red button "SUBSCRIBE TO LIVE STREAMING", check the Privacy Notice and the confirm.
You can enjoy the LIVE STREAMING for free on 5th and 6th November 2026.

RESIDENTIAL EVENT

IF YOU ARE ALREADY A SUBSCRIBER TO THE FONDAZIONE MENARINI RESERVED AREA

You can access the APP with the same username and password that you use on the website. Visit the page of the event and confirm your participation, click on "SUBSCRIBE TO RESIDENTIAL EVENT".
As you will be redirected to the **Fondazione Menarini website**, please follow the instructions above for RESIDENTIAL EVENT.

IF YOU ARE NOT YET A SUBSCRIBER, REGISTER FOR FREE IN THE FONDAZIONE MENARINI RESERVED AREA

Click on the profile icon in the top right-hand corner, or in the details of an event. Click on LOGIN:
Click on the red button REGISTER; to register in the reserved area, just fill in all the mandatory fields of the form.
Now it is necessary to log in with your username (email) and password! Then click on LOGIN.
Now you are logged-in to the APP (you will see your name near the user icon).
You can visit the schedule of the event by clicking on the red button "SUBSCRIBE TO RESIDENTIAL EVENT"
As you will be redirected to the **Fondazione Menarini website**, please follow the instructions above for RESIDENTIAL EVENT.

—

Please feel free to contact us if you need any further information or require any assistance, by clicking on the link below:

www.fondazione-menarini.com/en/contact-us.html

GENERAL INFORMATIONS

VENUE
The venue for the Meeting will be Auditorium Fondazione Menarini
Piazza Giuseppe Garibaldi, 30, 50014 Fiesole FI (Italy)

WIFI
Wifi: Guest
Password: Event-26

SECRETARIAT
The Secretariat will be open at the following times:
Thursday, 5 November from 08.15 a.m. to 6.15 p.m.
Friday, 6 November from 08.45 a.m. to 5.30 p.m.

OFFICIAL LANGUAGE
The official language of the Meeting will be English. No simultaneous interpretation.

REGISTRATION
The meeting is free to attend.
For more information and to register please visit the following website:
www.en.fondazione-menarini.it

TECHNICAL FACILITIES
Facilities will be available for computer presentations and overhead projections.
A business center with PC (Powerpoint for Windows) will be available for check and preview of presentations. It is essential that speakers take their presentation to the business center at least one hour before the session starts.

The center will be open at the following times:
Thursday, 5 November from 08.15 a.m. to 6.15 p.m.
Friday, 6 November from 08.45 a.m. to 5.30 p.m.

LUNCHES AND COFFEE BREAKS
Lunches and welcome coffee will be served near the meeting area.

ATTENDANCE CERTIFICATE AND SURVEY
At the end of each day, faculty members and participants will have the possibility to answer a short appreciation questionnaire accessible using the QR code projected on the screen. After completing the survey it will immediately be possible to download the Attendance Certificate which can be kept, printed and shared.

FONDAZIONE
MENARINI



www.fondazione-menarini.com

All slides and presentations are available on our website 15 days after the event.

CO-ORGANIZED BY

FONDAZIONE
MENARINI



Follow us on: WWW.FONDAZIONE-MENARINI.COM

Scan the QR code and
immediately download
the new APP.

Available on the App Store

GET IT ON Google play

Fondazione
Menarini
is also on LinkedIn

agfmilano.com